Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirogacestat in Recurrent Ovarian Granulosa Cell Tumors
NCT05348356Phase 2Completed
- Sponsor
- SpringWorks Therapeutics
- Start
- Aug 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of nirogacestat in ovarian granulosa cell tumor (OGCT), sponsored by SpringWorks Therapeutics. Started Aug 2022; status: completed.
02
Drugs
nirogacestat
03
Conditions
ovarian granulosa cell tumor (OGCT)
Beyond the preview
Go deeper on NCT05348356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05348356.